Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines

Cancer Letters

Volumn 241, Issue 2, 2006, Pages 213-220

  Imura, Masayoshi ^a,b   Yamashita, Satoshi ^a   Cai, Li yi ^a   Furuta, Jun ichi ^a   Wakabayashi, Mika ^a   Yasugi, Toshiharu ^b   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Demethylation; DNA methylation; Epigenetics; Gene expression; Ovarian cancers

Indexed keywords

BRCA1 PROTEIN; DNA; GLUTATHIONE TRANSFERASE P1; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN; PROTEIN CDKN2A; PROTEIN ESR1; PROTEIN FLNC; PROTEIN HAND1; PROTEIN HRASLS; PROTEIN LOX; PROTEIN MAGE B2; PROTEIN MLH1; PROTEIN TERC; PROTEIN THBD; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CARCINOMA CELL; CELL LINE; CONTROLLED STUDY; DEMETHYLATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; METHYLATION; MUCINOUS CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; UNDIFFERENTIATED CARCINOMA;

DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 33746707463     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.010     Document Type: Article

References (39)

1. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
2. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
3. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
4. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., and Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93 (1996) 7149-7153
5. Kaneda A., Tsukamoto T., Takamura-Enya T., Watanabe N., Kaminishi M., Sugimura T., et al. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci. 95 (2004) 58-64
6. dos Santos N.R., Torensma R., de Vries T.J., Schreurs M.W., de Bruijn D.R., Kater-Baats E., et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 60 (2000) 1654-1662
7. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J. Clin. 54 (2004) 8-29
8. Catteau A., Harris W.H., Xu C.F., and Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999) 1957-1965
9. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92 (2000) 564-569
10. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60 (2000) 5329-5333
11. Chan K.Y., Ozcelik H., Cheung A.N., Ngan H.Y., and Khoo U.S. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 62 (2002) 4151-4156
12. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., and Buller R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl Cancer Inst. 94 (2002) 61-67
13. Buller R.E., Shahin M.S., Geisler J.P., Zogg M., De Young B.R., and Davis C.S. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin. Cancer Res. 8 (2002) 1196-1202
14. O'Doherty A.M., Church S.W., Russell S.E., Nelson J., and Hickey I. Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br. J. Cancer 86 (2002) 282-284
15. Geisler J.P., Goodheart M.J., Sood A.K., Holmes R.J., Hatterman-Zogg M.A., and Buller R.E. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98 (2003) 2199-2206
16. Shih Y.C., Kerr J., Liu J., Hurst T., Khoo S.K., Ward B., et al. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int. J. Cancer 70 (1997) 508-511
17. Ryan A., Al-Jehani R.M., Mulligan K.T., and Jacobs I.J. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol. Oncol. 68 (1998) 14-17
18. Niederacher D., Yan H.Y., An H.X., Bender H.G., and Beckmann M.W. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br. J. Cancer 80 (1999) 1920-1926
19. Katsaros D., Cho W., Singal R., Fracchioli S., Rigault De La Longrais I.A., Arisio R., et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol. Oncol. 94 (2004) 685-692
20. Yoon J.H., Dammann R., and Pfeifer G.P. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94 (2001) 212-217
21. Agathanggelou A., Honorio S., Macartney D.P., Martinez A., Dallol A., Rader J., et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20 (2001) 1509-1518
22. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 158 (2001) 1121-1127
23. Rathi A., Virmani A.K., Schorge J.O., Elias K.J., Maruyama R., Minna J.D., et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 8 (2002) 3324-3331
24. Widschwendter M., Jiang G., Woods C., Muller H.M., Fiegl H., Goebel G., et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 64 (2004) 4472-4480
25. Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., and Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA 92 (1995) 7416-7419
26. Esteller M., Corn P.G., Urena J.M., Gabrielson E., Baylin S.B., and Herman J.G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58 (1998) 4515-4518
27. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., and Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59 (1999) 793-797
28. Hoare S.F., Bryce L.A., Wisman G.B., Burns S., Going J.J., van der Zee A.G., et al. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res. 61 (2001) 27-32
29. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59 (1999) 798-802
30. Kaneda A., Kaminishi M., Yanagihara K., Sugimura T., and Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 62 (2002) 6645-6650
31. Tsao S.W., Mok S.C., Fey E.G., Fletcher J.A., Wan T.S., Chew E.C., et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp. Cell Res. 218 (1995) 499-507
32. Tsao S.W., Wong N., Wang X., Liu Y., Wan T.S., Fung L.F., et al. Nonrandom chromosomal imbalances in human ovarian surface epithelial cells immortalized by HPV16-E6E7 viral oncogenes. Cancer Genet. Cytogenet. 130 (2001) 141-149
33. Kaneda A., Kaminishi M., Sugimura T., and Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett. 212 (2004) 203-210
34. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95 (1998) 14863-14868
35. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5 (2005) 223-231
36. Suh S.I., Cho J.W., Baek W.K., Suh M.H., and Carson D.A. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett. 153 (2000) 175-182
37. Milde-Langosch K., Ocon E., Becker G., and Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer 79 (1998) 61-65
38. Miyamoto K., Fukutomi T., Asada K., Wakazono K., Tsuda H., Asahara T., et al. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn. J. Clin. Oncol. 32 (2002) 79-84
39. Ushijima T., Watanabe N., Shimizu K., Miyamoto K., Sugimura T., and Kaneda A. Decreased fidelity in replicating CpG methylation patterns in cancer cells. Cancer Res. 65 (2005) 11-17